Doctor Care Anywhere Acquires £5.3m UK Weight-Loss Business to Boost Growth

Strategic Acquisition Expands UK Weight Management Presence

Doctor Care Anywhere Group PLC (ASX:DOC) has made a decisive move into the fast-growing UK weight management market by acquiring the GLP-1 and medicated weight-loss business of Outcome Diagnostics Limited and MedicSpot Limited for £850,000 (approximately A$1.7 million). This deal brings an established direct-to-consumer (D2C) platform with trailing 12-month revenue of £5.3 million (~A$11 million) and a broadly breakeven standalone EBITDA, representing a bargain 0.16x enterprise value to sales multiple.

The acquisition, funded entirely from DCA’s healthy cash reserves of £7 million as of March 2026, delivers immediate revenue and adds a high-performing 11-person team with proven execution in a competitive digital weight-loss market. This move aligns with DCA’s growth strategy outlined at its recent AGM and FY2025 results, aiming to broaden its consumer health offerings beyond telehealth consultations.

Direct-to-Consumer Capabilities and Cross-Selling Opportunities

Bringing the ODL and MedicSpot business in-house not only expands DCA’s service portfolio but also enhances its direct-to-consumer capabilities, a critical growth vector for the company. The acquired team has demonstrated strong customer acquisition and service cost metrics since launching in October 2024, positioning DCA to accelerate its D2C expansion across existing virtual GP, mental health, physiotherapy, and health assessment products.

CEO Laura O’Riordan highlighted the synergy potential, stating the combined teams will focus on integrating services and driving customer growth through cross-selling. This approach could deepen engagement with existing users and attract new patients seeking medicated weight-loss solutions, a sector showing robust demand in the UK market.

Financial Position and Growth Momentum

The deal’s funding from existing cash and ongoing positive operating cash flows avoids dilution or additional debt, underscoring DCA’s strengthened financial position following a series of profitable quarters and improved margins. Recent quarterly reports showed sustained consultation growth and cashflow improvements, with the company reaffirming ambitious medium-term targets including revenue doubling and a 15% EBITDA margin positive cashflow for the fourth quarter.

Chairman John Stier praised the executive leadership for swiftly capturing this strategic opportunity, leveraging DCA’s market position and balance sheet to accelerate growth. The acquisition’s straightforward structure; with no earn-out or deferred consideration; reduces complexity but also limits upside contingent on performance.

Integration Risks and Market Positioning

While the acquisition brings clear benefits, integration and execution risks remain. The company acknowledged these could impact timelines and results. How smoothly the ODL and MedicSpot teams integrate with DCA’s existing operations will be key to realising expected cross-selling synergies and sustaining growth momentum.

The transaction also signals DCA’s ambition to build a diversified consumer health business that leverages digital platforms across multiple therapeutic areas. This strategy follows the company’s recent trajectory of expanding clinical services and improving operational efficiency first profitable year, positioning it well against competitors in the UK telehealth and weight management sectors.